Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study

[1]  R. Roth,et al.  Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus) , 1997, Neuroscience.

[2]  R. Roth,et al.  Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease , 1997, Experimental Neurology.

[3]  C. Goetz,et al.  Dopaminergic Transplants in Patients with Parkinson's Disease: Neuroanatomical Correlates of Clinical Recovery , 1997, Experimental Neurology.

[4]  R. Todd,et al.  Dynamic Changes in Striatal Dopamine D2 and D3 Receptor Protein and mRNA in Response to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Denervation in Baboons , 1996, The Journal of Neuroscience.

[5]  T. Di Paolo,et al.  Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. , 1996, Molecular pharmacology.

[6]  Y. Agid,et al.  Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. , 1996, Brain research. Molecular brain research.

[7]  R. Roth,et al.  Early gestational mesencephalon grafts, but not later gestational mesencephalon, cerebellum or sham grafts, increase dopamine in caudate nucleus of MPTP-treated monkeys , 1996, Neuroscience.

[8]  C. Olanow,et al.  Fetal nigral transplantation as a therapy for Parkinson's disease , 1996, Trends in Neurosciences.

[9]  R. Roth,et al.  Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys. , 1996, Cell transplantation.

[10]  J. Bolam,et al.  Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  H. Kung,et al.  Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  P. Gaspar,et al.  D1 and D2 Receptor Gene Expression in the Rat Frontal Cortex: Cellular Localization in Different Classes of Efferent Neurons , 1995, The European journal of neuroscience.

[13]  J. Rosenstein.  Why Do Neural Transplants Survive? An Examination of Some Metabolic and Pathophysiological Considerations in Neural Transplantation , 1995, Experimental Neurology.

[14]  P. Seth,et al.  Neurobehavioural, neurochemical and electrophysiological studies in 6-hydroxydopamine lesioned and neural transplanted rats , 1995, International Journal of Developmental Neuroscience.

[15]  J. Obeso,et al.  MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration , 1994, Neuroscience Letters.

[16]  R. Roth,et al.  Novel Radioligands for the Dopamine Transporter Demonstrate the Presence of Intrastriatal Nigral Grafts in the MPTP-Treated Monkey: Correlation with Improved Behavioral Function , 1994, Experimental Neurology.

[17]  R. Ridley,et al.  Behavioral Assessment of the Effects of Embryonic Nigral Grafts in Marmosets with Unilateral 6-OHDA Lesions of the Nigrostriatal Pathway , 1994, Experimental Neurology.

[18]  B. Weiss,et al.  Lesions of Mouse Striatum Induced by 6‐Hydroxydopamine Differentially Alter the Density, Rate of Synthesis, and Level of Gene Expression of D1 and D2 Dopamine Receptors , 1994, Journal of neurochemistry.

[19]  S. Sesack,et al.  Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  M. Sofroniew,et al.  Trophism, Transplantation, and Animal Models of Parkinson's Disease , 1993, Experimental Neurology.

[21]  R. Schwartzman,et al.  Changes in brain dopamine receptors in MPTP parkinsonian monkeys followingL-dopa treatment , 1993, Brain Research.

[22]  D. Spencer,et al.  Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Future a , 1993, Annals of the New York Academy of Sciences.

[23]  J. Morrison,et al.  Heterogeneous distribution of D1, D2 and D5 receptor mRNAs in monkey striatum , 1993, Brain Research.

[24]  R. Roth,et al.  Fetal Dopamine Cell Survival after Transplantation Is Dramatically Improved at a Critical Donor Gestational Age in Nonhuman Primates , 1993, Experimental Neurology.

[25]  C D Marsden,et al.  Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study , 1993, Synapse.

[26]  M. Sambrook,et al.  Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism , 1993, Brain Research.

[27]  J. Joyce.  Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases , 1993, Brain Research.

[28]  J. Morrison,et al.  Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum. , 1992, Brain research. Molecular brain research.

[29]  R. Schwartzman,et al.  Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys , 1992, Brain Research.

[30]  P. Bédard,et al.  Decrease of behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants , 1991, Neuroscience.

[31]  O. Hornykiewicz,et al.  Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey , 1991, Neuroscience.

[32]  M. Martinoli,et al.  Regional changes of striatal dopamine receptors following denervation by 6-hydroxydopamine and fetal mesencephalic grafts in the rat , 1991, Brain Research.

[33]  J. Joyce.  Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system , 1991, Experimental Neurology.

[34]  R. Schwartzman,et al.  Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates , 1991, Brain Research.

[35]  K. Neve,et al.  Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F. Gage,et al.  Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra , 1991, Experimental Neurology.

[37]  A. Northrop,et al.  Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway—III. Reversal by embryonic nigral dopamine grafts , 1990, Neuroscience.

[38]  J. Schneider.  Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys , 1990, Brain Research.

[39]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[40]  A. Levey,et al.  Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Abercrombie,et al.  Effects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats , 1990, Brain Research.

[42]  T. Robinson,et al.  Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  A. Alavi,et al.  The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  S. Boyce,et al.  Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis) , 1990, Brain Research.

[45]  R. Roth,et al.  Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions , 1989, Neuroscience.

[46]  T. Di Paolo,et al.  Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. , 1988, European journal of pharmacology.

[47]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[48]  P. Bédard,et al.  Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys , 1988, Neuroscience Letters.

[49]  M. Savasta,et al.  Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission , 1988, Neuroscience Letters.

[50]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[51]  R. Robertson,et al.  MPTP-Induced Parkinsonism in the Monkey: Neurochemical Pathology, Complications of Treatment and Pathophysiological Mechanisms , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[52]  R. Roth,et al.  Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. , 1987, Life sciences.

[53]  D. Jacobowitz,et al.  Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density , 1986, Brain Research.

[54]  T. Paolo,et al.  Chronic treatment withl-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding , 1986, Brain Research.

[55]  Y Agid,et al.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. , 1984, European journal of pharmacology.

[56]  W. Freed,et al.  Normalization of spiroperidol binding in the denervated rat striatum by homologous grafts of substantia nigra. , 1983, Science.

[57]  O. Hornykiewicz,et al.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.

[58]  B. Ghetti,et al.  Ventral mesencephalic grafts in the neostriatum of the weaver mutant mouse: structural molecule and receptor studies. , 1995, Cell transplantation.

[59]  R. Roth,et al.  Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. , 1995, Cell transplantation.

[60]  P. Sanberg,et al.  Cell transplantation for central nervous system disorders. , 1994, Critical reviews in neurobiology.